Search
Displaying 141–150 of 689 for “retinitis clinical trial”
-
Information for affected individuals and their families about the role of genetic counseling.
-
Recap of Retinal Disease News from the 2022 Meeting of the American Academy of Ophthalmology
Research NewsReports on emerging therapies for dry age-related macular degeneration (geographic atrophy), Stargardt disease, and X-linked retinitis pigmentosa are included
-
Adverum Advancing Wet AMD Gene Therapy into Phase 3 Clinical Trials
Research NewsIn earlier clinical trials, the emerging gene therapy greatly reduced the treatment burden associated with injections of approved anti-VEGF therapies.
-
Over Thirty Presentations Highlighted during the 2022 Retinal Cell & Gene Therapy Innovation Summit
Research NewsIn its seventh year, the Retinal Cell & Gene Therapy Innovation Summit featured 34 presentations from industry experts from around the world.
-
Acucela Enrolling Patients in Phase 3 Trial for Stargardt Disease Treatment
Research NewsThe Seattle biotech Acucela is now enrolling participants in its Phase 3 clinical trial for emixustat hydrochloride, an emerging oral drug for slowing vision loss in people with Stargardt disease, an inherited form of a macular degeneration.
-
AGTC Plans Further Clinical Development of Achromatopsia (CNGB3) Gene Therapy
Research NewsInterim results for pediatric patients with CNGB3 mutations were encouraging
-
Vision Improvements Reported in Early Stem Cell Trial for Wet AMD
Research NewsTwo patients with advanced wet age-related macular degeneration (AMD) in a Phase I clinical trial demonstrated improved visual acuity sustained for one year after a sheet of retinal pigment epithelial (RPE) cells derived from embryonic stem cells was transplanted under their retinas. Each patient had one eye treated. Vision improvement for one patient was 29 letters or about 6 lines on an eye chart. The other had a gain of 21 letters or about 4 lines.
-
Iveric Bio’s Therapy Slows Retinal Degeneration in Phase 2b Trial for Dry AMD
Research NewsZimura inhibits a complement protein known as C5, a component of the immune system that, when overactive, can cause retinal degeneration.
-
Ophthotech is Advancing an Impressive Portfolio of Cutting-Edge Therapies for Retinal Diseases
Research NewsThe company is taking on a multi-track strategy that includes retinal gene-therapy development, including delivery of over-sized genes and design of a two-step process of gene knockdown and replacement for autosomal dominant conditions.
-
Disease
Often diagnosed in childhood or adolescence, retinitis pigmentosa (RP) is an inherited retinal disease causing progressive loss of night and peripheral vision. The condition often leads to legal and sometimes complete blindness.
.png)
